Targeted pill plus chemotherapy before surgery for early lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted pill (zipalertinib) combined with standard chemotherapy (carboplatin and pemetrexed) before surgery for early-stage lung cancer with specific EGFR mutations. It aims to shrink the tumor and potentially improve outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to consent.
- You must have stage II, IIIA, or IIIB (N2) non-small cell lung cancer that can be surgically removed.
- Your tumor must have a specific EGFR mutation (like exon 20 insertion or certain uncommon types).
- You cannot have had previous systemic treatment (like chemotherapy or targeted pills) for lung cancer.
- You need to be in generally good health with adequate organ function (kidney, liver, blood counts).
- No history of lung inflammation (pneumonitis) or other conditions that might interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different treatment plans before lung cancer surgery. Both plans start with a targeted pill (limertinib), then one adds immunotherapy plus chemotherapy, and the other adds just chemotherapy. The goal is to see which combination helps shrink the tumor more before surgery.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This study tests whether taking zipalertinib after lung cancer surgery can help prevent the cancer from coming back in people whose tumors have uncommon EGFR gene changes. It is a pill taken daily after recovery from surgery.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This trial tests giving chemotherapy followed by the immunotherapy drug sintilimab before surgery for people with EGFR-mutant, early-stage non-small cell lung cancer. It aims to see if this combination reduces the tumor and improves outcomes before surgical removal.
This trial tests zipalertinib, a targeted pill for people with non-small cell lung cancer that has an atypical EGFR gene change. It is given after standard treatment like surgery or radiation to help prevent the cancer from coming back.
Hear when a new Lung Non-Squamous Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.